These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 33375873)
1. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873 [TBL] [Abstract][Full Text] [Related]
2. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Halford Z; Anderson MK; Bennett LL Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673 [TBL] [Abstract][Full Text] [Related]
3. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726 [TBL] [Abstract][Full Text] [Related]
5. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634 [TBL] [Abstract][Full Text] [Related]
6. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Westin JR; Oluwole OO; Kersten MJ; Miklos DB; Perales MA; Ghobadi A; Rapoport AP; Sureda A; Jacobson CA; Farooq U; van Meerten T; Ulrickson M; Elsawy M; Leslie LA; Chaganti S; Dickinson M; Dorritie K; Reagan PM; McGuirk J; Song KW; Riedell PA; Minnema MC; Yang Y; Vardhanabhuti S; Filosto S; Cheng P; Shahani SA; Schupp M; To C; Locke FL; ; N Engl J Med; 2023 Jul; 389(2):148-157. PubMed ID: 37272527 [TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286 [TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867 [TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry. Ray M; Castaigne JG; Zang A; Patel A; Hancock E; Brighton N; Bachy E Adv Ther; 2024 Nov; 41(11):4282-4298. PubMed ID: 39316290 [TBL] [Abstract][Full Text] [Related]
12. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402 [TBL] [Abstract][Full Text] [Related]
13. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322 [TBL] [Abstract][Full Text] [Related]
14. Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven. Brijs J; Van Ham J; Dubois B; Sinap F; Vergote V; Dierickx D; Vandenberghe P Acta Clin Belg; 2024 Aug; 79(4):276-284. PubMed ID: 39415456 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993 [TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581 [TBL] [Abstract][Full Text] [Related]
18. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532 [TBL] [Abstract][Full Text] [Related]
19. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Lunning MA; Wang HL; Hu ZH; Locke FL; Siddiqi T; Jacobson CA; Ahmed S; Miklos DB; Lin Y; Hill BT; Ghobadi A; Neelapu SS; Westin J; Dieyi C; Field P; Miao H; Shahani SA; Patel A; Spooner C; Fu C; Muramoto D; Xu H; Pasquini MC Am J Hematol; 2024 May; 99(5):880-889. PubMed ID: 38504387 [TBL] [Abstract][Full Text] [Related]
20. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]